CAS: 5104-49-4; 2-(2-Fluoro-[1,1'-Biphenyl]-4-yl)Propanoic Acid

该化合物是一种非类固醇抗炎药物(NSAID) , 提供有效的止痛和抗炎特性. 它对环氧酶酶的强烈抑制可以有针对性地缓解疼痛和炎症,而它的迅速行动和短暂的半衰期可以最大限度地减少肠胃的副作用.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

(R)-3-O-(2-(2-fluoro-4-biphenyl)propionyl)-1,2-O-isopropylidene-α-D-glucofuranose (S)-3-O-(2-(2-fluoro-4-biphenyl)propionyl)-1,2-O-isopropylidene-α-D-glucofuranose (R)-3-O-(2-(2-fluoro-4-biphenylyl)propionyl)-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose methyl 2-(2-fluoro-4-biphenylyl)propionate(S)-(+)-flurbiprofen (R)-flurbiprofen methyl 2-(2-fluoro-biphenyl-4-yl)propionate methyl 2-(2-fluoro-biphenyl-4-yl)propionate

合成工艺路线路线简述

    乙基6,7-二甲氧基-3-甲基-4-氧代-1-(3,4,5-三甲氧基苯基)-1,2,3,4-四氢-2-萘l烯羧酸酯置于硫酸,水体系中,用 1,4-二氧六环 作为反应溶剂,化学反应 4.0H,以99%的收率获得产物氟比洛芬
    参考文献:金催化有机金属的氧化联芳基交叉偶联
    标题:金催化有机金属的氧化联芳基交叉偶联
    摘要:联芳基亲核试剂之间的偶联(ar δ-:Arylboronates或芳基硅烷)和亲电(ar δ+:芳基卤化物)代表了碳-碳键形成的最新技术.这些反应中固有的官能团限制源于钯和镍催化剂对卤素,硼酸酯和碱敏感取代基的高催化反应性.在这里,我们报告了一般的二聚体金催化的芳基硼酸酯和芳基硅烷的氧化交叉偶联反应,而没有用于合成的外部碱,具有不对称联芳基的优异的官能团耐受性.两种偶合剂均易于获得,稳定且无毒.各种各样的(假)卤代和硼化偶合剂可以成功地应用于这种位点特定的联芳基偶合剂,具有前所未有的多功能性.简明地制备几种π共轭有机材料和药效基团已证实了其合成价值.
    DOI:10.1016/j.Chempr.2019.07.023

    海关参考信息

    专利信息


    专利号:US-2012177593-A1
    优先权日:2009-07-20
    标 题 :Synthesis of dendrimer conjugates
    发明人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
    权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
    摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

    专利号:US-8546532-B2
    优先权日:2008-04-17
    标题:Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
    发明人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS
    权利人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS; DECLION PHARMACEUTICALS INC
    摘要:The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder.

    专利号:US-2012029226-A1
    优先权日:2009-02-06
    标题:Method for the synthesis of chiral alpha-aryl propionic acid derivatives
    发明人:KAPTEIN BERNARDUS; VLIEG ELIAS; NOORDUIN WILLEM LIEUWE
    权利人:KAPTEIN BERNARDUS; VLIEG ELIAS; NOORDUIN WILLEM LIEUWE
    摘要:The present invention provides a method for the synthesis of optically pure α-aryl propionic acid derivatives comprising subjecting the corresponding racemic α-aryl propionic acid derivatives to high sheer or impact forces, such as grinding.

    专利号:US-12264143-B2
    优先权日:2020-12-17
    标 题:Synthesis of cannabinoids and cannabinoid precursors, and related compounds, formulations, and methods of use
    发明人:SAMMIS GLENN M; ROGGEN MARKUS
    权利人:NALU BIO INC
    摘要:Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

    专利号:US-5043328-A
    优先权日:1986-05-09
    标 题 :Formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems
    发明人:WEITHMANN KLAUS U
    权利人:HOECHST AG
    摘要:The present invention relates to formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems and to the use of such formulations for the preparation of medicaments which are suitable for curing prostaglandin deficiencies in humans or animal, for example healing or preventing diseases of the gastro-intestinal tract.

    专利号:US-2024082118-A1
    优先权日:2021-05-19
    标 题:Topical compositions and methods of preparing the same
    发明人:ABRAMOVICH SAGI; AVIDOR GAL; LANDA BENZION
    权利人:LANDA LABS 2012 LTD
    摘要:There is disclosed a composition comprising a water-insoluble thermoplastic compound capable of stimulating collagen synthesis (CSSC), the CSSC having a molecular weight of more than 0.6 kDa and being dispersed in a polar carrier as nano-elements having an average diameter of 200 nm or less and a viscosity of 107 mPa·s or less. The nano-elements of CSSC can be capable of stimulating the synthesis of skin proteins and/or enabling the delivery of active agents upon their application to a surface to be treated therewith. Methods for preparing the compositions and uses thereof are also provided.
    太仓运通生物化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.tcytchem.com
    电话: 0512-53640999👤
    📞太仓运通生物化工有限公司 ⚠️参考联系方式

    销售电话:0512-53640999
    邮箱:sales@tcytchem.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Abdel-Aziz AA, Al-Badr AA, Hafez GA. Flurbiprofen. Profiles Drug Subst Excip Relat Methodol. 2012;37:113-81. doi: 10.1016/B978-0-12-397220-0.00004-0. Epub 2012 Mar 19. 31(789):31-2. 32(1):76-80. doi: 10.1038/clpt.1982.129. 61(8):1396-406. doi: 10.1111/j.1742-1241.2007.01452.x. Epub 2007 Jun 26. 26(6):e723-e726. doi: 10.1097/MJT.0000000000000879. 28(2):100-14. doi: 10.2165/00003088-199528020-00002. 34(6):894-900. doi: 10.1002/chir.23441. Epub 2022 Apr 12. 80(3A):10-5. doi: 10.1016/0002-9343(86)90104-x.
    20:995-1002. doi: 10.12659/MSM.890102.
    10: Geerts H. Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. IDrugs. 2007 Feb;10(2):121-33. 18(6):417-38. doi: 10.2165/00003495-197918060-00001. 60(1):43-8. doi: 10.3949/ccjm.60.1.43. 48(2):400-8. doi: 10.1016/j.brainresrev.2004.12.029. Epub 2005 Jan 28. 5(1):85-7. doi: 10.1185/03007997709108982. 50(7):749-756. doi: 10.1007/s00595-019-01951-1. Epub 2020 Jan 10. 31(6):457-467. doi: 10.1002/chir.23071. Epub 2019 May 7. 27(6):707-712. doi: 10.1111/vec.12638. Epub 2017 Aug 23. 18(1):133. doi: 10.1186/s12944-019-1064-x.

    合成参考文献


    参考文献:10.1007/s00228-010-0784-7
    摘要:Chopade AR, Mulla WA. Novel strategies for the treatment of inflammatory hyperalgesia. European Journal of Clinical Pharmacology. 2010 Feb 13;66(5):429–44. doi: 10.1007/s00228-010-0784-7.
    参考文献:10.18632/aging.100021
    摘要:Choi SH, Bosetti F. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY). 2009 Feb 11;1(2):234–44.
    参考文献:10.2147/opth.s7633
    摘要:Reddy R, Kim SJ. Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery. Clin Ophthalmol. 2011;5():751–8.
    参考文献:10.1002/chir.20978
    摘要:Ribeiro AE, Gomes PS, Pais LS, Rodrigues AE. Chiral separation of flurbiprofen enantiomers by preparative and simulated moving bed chromatography. Chirality. 2011 Sep;23(8):602–11. doi: 10.1002/chir.20978.
    参考文献:10.4103/0972-124x.75908
    摘要:Dhadse P, Gattani D, Mishra R. The link between periodontal disease and cardiovascular disease: How far we have come in last two decades J Indian Soc Periodontol. 2010 Jul;14(3):148–54.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知